CYSTIC FIBROSIS CANADA WELCOMES HEALTH CANADA’S APPROVAL OF KALYDECO® FOR CHILDREN WITH G551D AND OTHER GATING MUTATIONS
http://www.cysticfibrosis.ca/wp-content/themes/Cystic-Fibrosis-Canada/img/FB_Share_Image.jpg
Calling for the manufacturer and drug insurance plans to ensure CF patients receive equitable and timely access to …
DONATECLOSE
GENERAL DONATIONS
MONTHLY
IN HONOUR
IN MEMORY
Join the CF fight
Cystic fibrosis is the most common fatal genetic disease
affecting Canadian children and young adults
LEARN MORE ABOUT CF > SEE HOW YOU CAN HELP >
Research brings hope
Innovative CF research is bringing us closer to
finding a cure or control
LEARN MORE ABOUT CF RESEARCH > SEE HOW YOU CAN HELP >
Clinical care improves lives
Cystic Fibrosis Canada funds 42 specialized
CF clinics across Canada
Learn more about CF clinical care > SEE HOW YOU CAN HELP >
Advocating for change
Together, we’re raising the voice of Canadians
with cystic fibrosis
LEARN MORE ABOUT ADVOCACY > SEE HOW YOU CAN HELP >
UPCOMING EVENTS
OUR PARTNERS
IN YOUR COMMUNITY
@cysticFibrosisCanada ORKAMBI™ the ivacaftor/lumacaftor combination therapy has been FDA approved for use in the US. Read more in our blog bit.ly/1IwbDWQ
Jul 2nd